EVO

Neutral

Evotec SE stock (DE0005664809): Nasdaq relisting and strategic reset keep biotech investors on edge

Evotec SE has re-entered the spotlight for US investors following its Nasdaq relisting and strategic updates. The company, which specializes in drug d...

AD HOC NEWS 16 hours ago 0

Bullish

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec SE has received two new grants from the Gates Foundation, totaling $9.9 million, to accelerate the discovery and development of novel tuberculo...

Investing News Network 3 weeks ago 0